Index
-
Market Cap
74.70M
Enterprise Value
117.90M
Income
-9.47M
Sales
23.14M
Book/sh
-4.38
Cash/sh
0.93
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
14
IPO
Oct 16, 2014
P/E
-
Forward P/E
9.26
PEG
-
P/S
3.23
P/B
-
P/C
8.94
P/FCF
-
EV/EBITDA
-
EV/Sales
5.10
Quick Ratio
2.16
Current Ratio
2.16
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-0.88
EPS next Y
0.90
EPS next Q
-0.32
EPS this Y
-150.39%
EPS next Y
169.11%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
23.85% -
EPS Y/Y TTM
76.14%
Sales Y/Y TTM
-88.41%
EPS Q/Q
-108.40%
Sales Q/Q
-99.47%
Insider Own
33.40%
Insider Trans
6.41%
Inst Own
48.40%
Inst Trans
1.03%
ROA
-23.08%
ROE
-
ROIC
-75.60%
Gross Margin
96.12%
Oper. Margin
-26.42%
Profit Margin
-40.91%
SMA20
-17.05%
SMA50
-16.24%
SMA200
-14.81%
Trades
Shs Outstand
8.51M
Shs Float
6.00M
52W High
19.15 -56.70%
52W Low
3.92 111.48%
Volatility
8.95% 8.08%
ATR (14)
0.79
RSI (14)
38.61
Beta
0.14
Rel Volume
0.04
Avg Volume
1.43M
Volume
59,221
Perf Week
-4.38%
Perf Month
-14.27%
Perf Quarter
57.31%
Perf Half Y
79.44%
Perf YTD
-54.17%
Perf Year
-17.10%
Perf 3Y
-83.98%
Perf 5Y
-97.48%
Perf 10Y
-98.49%
Prev Close
8.39
Price
8.29
Change
-1.19%
Date
Action
Analyst
Rating Change
Price Target Change
May-08-26 Upgrade Canaccord Genuity
Hold → Buy
$13
Jan-13-26 Downgrade Canaccord Genuity
Buy → Hold
$6
Nov-09-23 Downgrade Mizuho
Buy → Neutral
$31 → $1
Nov-09-23 Downgrade H.C. Wainwright
Buy → Neutral
Nov-09-23 Downgrade Evercore ISI
Outperform → In-line
Jul-20-22 Downgrade Citigroup
Neutral → Sell
$8 → $3
Jul-13-22 Downgrade Stifel
Buy → Hold
$16 → $5
Jul-13-22 Downgrade JP Morgan
Overweight → Neutral
$10
May-10-22 Downgrade Citigroup
Buy → Neutral
$15 → $8
May-13-21 Upgrade JP Morgan
Neutral → Overweight
$23 → $29
Dec-09-20 Downgrade Citigroup
Buy → Neutral
$20 → $27
Dec-08-20 Reiterated H.C. Wainwright
Buy
$28 → $31
Nov-10-20 Reiterated H.C. Wainwright
Buy
$26 → $28
Jun-30-20 Initiated Evercore ISI
Outperform
Jun-15-20 Initiated H.C. Wainwright
Buy
$25
Apr-23-20 Upgrade Citigroup
Neutral → Buy
$14
Nov-08-19 Downgrade JP Morgan
Overweight → Neutral
$43 → $22
Sep-27-19 Downgrade Goldman
Neutral → Sell
$14 → $9
Sep-16-19 Downgrade Jefferies
Buy → Hold
$32 → $15
Jun-04-19 Upgrade Citigroup
Sell → Neutral
$23 → $24
Show Previous Ratings
Jun-12-26 04:00PM
May-20-26 09:00AM
May-12-26 04:40PM
(Associated Press)
+11.73%
+6.83%
04:05PM
May-07-26 11:03AM
10:30AM
Loading…
10:30AM
08:05AM
Apr-16-26 06:10PM
Apr-01-26 09:00AM
Mar-26-26 07:30AM
Mar-16-26 04:35PM
(Associated Press Finance)
-9.69%
-10.90%
04:05PM
Mar-12-26 08:05AM
Mar-03-26 08:05AM
06:52AM
08:00AM
Loading…
Feb-23-26 08:00AM
Jan-12-26 11:06AM
08:00AM
06:24AM
Nov-12-25 09:11AM
(Associated Press Finance)
09:00AM
Nov-10-25 08:45AM
Nov-07-25 06:45AM
Nov-06-25 06:10PM
Nov-05-25 06:25PM
Nov-03-25 09:00AM
Sep-25-25 09:28AM
Sep-03-25 06:00PM
Aug-19-25 05:00AM
Aug-11-25 05:53PM
(Associated Press Finance)
-5.80%
+11.82%
04:01PM
Loading…
04:01PM
Jul-24-25 08:57AM
08:00AM
06:55AM
Jul-15-25 08:00AM
06:31AM
Jul-14-25 08:00AM
May-16-25 08:50PM
May-15-25 08:58AM
(Associated Press Finance)
+15.13%
08:35AM
08:30AM
May-14-25 08:25AM
May-13-25 09:10AM
May-05-25 05:06PM
(Business Wire)
-7.29%
+5.79%
Apr-10-25 08:52AM
Mar-13-25 12:00PM
Mar-07-25 05:10PM
04:16PM
(Associated Press Finance)
04:01PM
Feb-14-25 09:55AM
08:11AM
Feb-07-25 04:01PM
Jan-22-25 05:00AM
Jan-21-25 01:11PM
07:30AM
Jan-17-25 07:00AM
Jan-16-25 12:28PM
08:30AM
Jan-02-25 12:00PM
Dec-04-24 07:00AM
Dec-03-24 07:00AM
Nov-27-24 04:01PM
Nov-13-24 04:01PM
(Business Wire)
+22.19%
-10.45%
Nov-12-24 05:15PM
04:13PM
(Associated Press Finance)
04:01PM
Nov-05-24 04:01PM
Oct-15-24 12:00PM
Oct-04-24 04:01PM
Sep-30-24 03:16AM
Sep-13-24 07:02PM
(GuruFocus.com)
+20.30%
-11.52%
Sep-06-24 04:01PM
(Business Wire)
-5.30%
-5.28%
Sep-04-24 04:01PM
(Business Wire)
+32.89%
+10.50%
Sep-03-24 04:16PM
Aug-12-24 06:10PM
05:07PM
(Associated Press Finance)
05:00PM
Aug-07-24 04:01PM
Jul-19-24 06:12AM
(Pharmaceutical Technology)
Jul-17-24 04:13PM
(Pharmaceutical Technology)
-12.82%
09:00AM
07:00AM
Jul-16-24 07:00AM
Jul-15-24 12:00PM
Jul-05-24 04:01PM
Jul-03-24 07:57PM
Jun-21-24 04:01PM
Jun-17-24 08:00AM
Jun-12-24 07:00AM
Jun-11-24 07:00AM
Jun-07-24 04:01PM
Jun-05-24 04:01PM
May-29-24 04:01PM
May-20-24 11:57AM
09:25AM
May-09-24 10:57PM
05:15PM
04:17PM
(Associated Press Finance)
04:01PM
May-03-24 04:01PM
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
President Dr. Anhco Nguyen Ph.D.
Interim Chief Financial Officer Mr. Kevin G. Sarney CPA
Vice President of Corporate Communications & Investor Relations Alex Chapman
Head of Legal Mr. John Chao
Senior Vice President of Regulatory Affairs Mr. Jim Sesic
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Nguyen AnhCo President and CEO May 18 '26 Sale 9.13 5,241 47,845 137,837 May 20 05:24 PM Grant-Huerta Yanina Chief Accounting Officer May 18 '26 Sale 9.13 2,414 22,036 49,636 May 20 05:24 PM Nguyen AnhCo Director May 18 '26 Proposed Sale 10.48 5,981 62,681 May 18 04:45 PM Grant-Huerta Yanina Officer May 18 '26 Proposed Sale 10.48 2,754 28,862 May 18 04:44 PM Panacea Innovation Ltd 10% Owner May 07 '26 Sale 10.10 313,446 3,165,021 1,011,000 May 11 06:45 PM EcoR1 Capital, LLC 10% Owner May 07 '26 Buy 9.35 507,407 4,744,255 1,552,000 May 11 05:34 PM Panacea Innovation Ltd 10% Owner May 07 '26 Proposed Sale 10.10 313,446 3,165,021 May 07 08:30 PM Panacea Innovation Ltd 10% Owner Mar 17 '26 Option Exercise 0.00 259,163 26 307,899 Mar 19 04:30 PM Grant-Huerta Yanina Chief Accounting Officer Mar 02 '26 Sale 5.08 2,104 10,691 31,750 Mar 04 04:28 PM Nguyen AnhCo President and CEO Mar 02 '26 Sale 5.09 2,996 15,237 61,978 Mar 04 04:28 PM Nguyen AnhCo Director Mar 02 '26 Proposed Sale 5.42 3,355 18,184 Mar 02 06:25 PM Grant-Huerta Yanina Officer Mar 02 '26 Proposed Sale 5.42 2,355 12,764 Mar 02 06:24 PM Panacea Innovation Ltd 10% Owner Jan 12 '26 Sale 6.07 80,554 489,019 1,324,446 Jan 14 09:16 PM Panacea Innovation Ltd 10% Owner Jan 12 '26 Proposed Sale 5.88 40,000 235,200 Jan 12 09:26 PM Panacea Innovation Ltd 10% Owner Nov 28 '25 Option Exercise 0.00 48,737 5 48,737 Dec 01 05:00 PM Nguyen AnhCo President and CEO Nov 17 '25 Sale 13.19 2,915 38,437 64,974 Nov 19 04:55 PM Grant-Huerta Yanina Chief Accounting Officer Nov 17 '25 Sale 13.19 1,804 23,788 33,454 Nov 19 04:55 PM Nguyen AnhCo Director Nov 17 '25 Proposed Sale 13.76 3,346 46,041 Nov 17 05:52 PM Grant-Huerta Yanina Officer Nov 17 '25 Proposed Sale 13.76 2,069 28,469 Nov 17 05:50 PM Nguyen AnhCo President and CEO Aug 18 '25 Sale 11.62 2,958 34,360 67,889 Aug 20 04:11 PM Grant-Huerta Yanina Chief Accounting Officer Aug 18 '25 Sale 11.61 1,809 21,009 35,258 Aug 20 04:08 PM Panacea Innovation Ltd 10% Owner Aug 15 '25 Buy 12.19 55,000 670,422 1,405,000 Aug 19 08:15 PM Nguyen AnhCo Director Aug 18 '25 Proposed Sale 12.29 3,346 41,122 Aug 18 04:52 PM Grant-Huerta Yanina Officer Aug 18 '25 Proposed Sale 12.29 2,048 25,170 Aug 18 04:47 PM
A